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Background: MiR-221 and miR-222 (miR-221/222) are frequently up-regulated in various types of human
malignancy including glioblastoma. Recent studies have reported that miR-221/222 regulate cell growth and cell
cycle progression by targeting p27 and p57. However the underlying mechanism involved in cell survival
modulation of miR-221/222 remains elusive.
Results: Here we showed that miR-221/222 inhibited cell apoptosis by targeting pro-apoptotic gene PUMA in
human glioma cells. Enforced expression of miR-22/222 induced cell survival whereas knockdown of miR-221/222
rendered cells to apoptosis. Further, miR-221/222 reduced PUMA protein levels by targeting PUMA-3’UTR.
Introducing PUMA cDNA without 3′UTR abrogated miR-221/222-induced cell survival. Notably, knockdown of miR-
221/222 induces PUMA expression and cell apoptosis and considerably decreases tumor growth in xenograft
model. Finally, there was an inverse relationship between PUMA and miR-221/222 expression in glioma tissues.
Conclusion: To our knowledge, these data indicate for the first time that miR-221/222 directly regulate apoptosis
by targeting PUMA in glioblastoma and that miR-221/222 could be potential therapeutic targets for glioblastoma
intervention.
Background
MicroRNAs (miRNAs), a new class of small RNA (~22nt),
are thought to negatively regulate protein-coding genes by
base-pair matching with 3′UTR of mRNA. Growing
evidence has indicated that the important roles for miR-
NAs in the development of different cancers. Deregulation
of miRNAs has been observed in various types of human
malignancy, including lymphoma, colorectal cancer, lung
cancer, breast cancer, papillary thyroid carcinoma, hepato-
cellular carcinoma and glioblastoma [1-7]. And oncomiRs
and tumor suppressor miRNAs exert their functions
through regulation of tumor suppressor genes and onco-
genes, respectively [8-10].
Glioblastoma is one of the most common forms
of neural malignancy, with a median survival of 9-
12 months. Despite the significant toxicities of current
therapies, a large fraction of brain cancer patients suffer
tumor recurrence due to the resistance to chemo- and
radio-therapy [11-13]. Thus, there are urgent needs to
develop novel therapeutic approaches by targeting the
molecules that are altered in this malignancy. Recent
studies showed frequent deregulation of miR-221/222 in
glioblastoma [1,14]. We profiled miRNA expression in
five glioblastoma cell lines, one astrocytoma cell line
and one normal brain tissue, and found that miR-221/
222 were overexpressed with a greater than 2-fold
increase in all glioma cell lines [15]. We and others have
shown that miR-221/222 induce cell growth and cell
cycle progression through negative regulation of p27
and p57 [16-19]. In the current study, we have demon-
strated that miR-221/222 are of important role in regu-
lation of cell apoptosis by direct targeting pro-apoptotic
molecule PUMA in cell culture and xenograft model.
Knockdown of miR-221/222 induces apoptosis and
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expression. Whereas, ectopic expression of miR-221/222
exhibits opposite effects. Moreover, miR-221/222
directly interact with 3′UTR of PUMA to repress PUMA
expression. These findings indicate that PUMA is a
bona fide target of miR-221/222 and these 2 miRNAs
could be critical therapeutic targets for glioblastoma
intervention.
Results
Critical role of miR-221/222 in apoptosis pathway
Previous studies have documented miR-221 and miR-
222 regulation of cell cycle progression and cell prolif-
eration by targeting p27 and p57 [16-18]. However,
their role in apoptotic pathway has not been well stu-
died. As initial step, we carried out Northern blot analy-
sis of miR-221 and miR-222 expression in a panel of
glioma cell lines. Fig. 1A showed that U251, TJ866 and
TJ899 cells expressed higher levels of miR-221 and miR-
222 compared to other cell lines. To examine biological
significance of miR-221 and miR-222 in glioma, U251
and LN229 cells were treated with As-miR-221 and/or
As-miR-222 (Fig. 1B). Interestingly, annexin V-labeling
revealed that knockdown of miR-221 and miR-222 sig-
nificantly increased cell apoptosis compared to the cells
treated with scramble oligonucleotide (Fig. 1C). More-
over, Western blot assay displayed that pro-apoptotic
protein Bax expression was significantly up-regulated
while BCL2 expression was down-regulated in As-miR-
221/222 group (Fig. 1D). In addition, caspase 3/7 activity
was also considerably elevated in miR-221 and miR-222
knocked down cells (Fig. 1E). Since collapse of the mito-
chondrial membrane potential is one of the early events
in apoptosis [20], we next examined if miR-221 and
miR-222 regulate mitochondrial membrane potential.
The cells with depletion of miR-221 and miR-222 were
stained with cationic dye JC-1. FACSCalibur analysis
showed that the mitochondrial membrane potential was
largely damaged when miR-221 and miR-222 were
depleted (Fig. 1F). These findings indicate that miR-221
and miR-222 play an important role in initiation of cell
apoptosis.
PUMA is a target for miR-221 and miR-222
To determine the mechanism by which miR-221 and
miR-222 regulate cell apoptosis, we performed miRNA
target search using Pictar and found 3′UTR of PUMA
containing the highly conserved putative miR-221 and
miR-222 binding sites (Fig. 2A). Further, we knocked-
down miR-221/222 in U251 cells, which exhibit elevated
level of miR-221/222, and ectopically expressed miR-
221/222 in H4 cells with low endogenous miR-221/222
expression (Fig. 1A). Western blot analysis showed that
PUMA expression was up-regulated in U251 cells with
knockdown of miR-221/222 (Fig. 2B), whereas downre-
gulated in H4 cells overexpressing miR-221/222
(Fig. 2C), compared to the cell treated with scrambled
oligonucleotide or vector alone. Moreover, we created
pGL3-WT-PUMA-3′UTR and pGL3-MUT-PUMA-3′
UTR plasmids. Reporter assay revealed reduction of
miR-221/222 led to a marked increase of luciferase
activity of pGL3-WT-PUMA-3′UTR plasmid, without
change in luciferase activity of pGL3-MUT-PUMA-3′
UTR plasmid (Fig. 2D). PUMA recently identified as a
critical mediator of p53-associated apoptosis. Thus, we
further explored the effect of miR-221/222 on p53
expression. There was no change of p53 in U251 and
LN229 cells after reduction of miR-221/222 (Fig. 2E).
These indicate that miR-221/222 directly modulate
PUMA expression by binding 3′UTR of PUMA.
Expression of PUMA overrides miR-221/222 survival
function
Having demonstrated PUMA as a direct target of miR-
221 and miR-222, we next examined the importance of
PUMA in miR-221/222-mediated cell survival. Since H4
expressed low level of miR-221/222, we transfected
PUMA lacking 3′UTR together with and without miR-
221 and miR-222 into the H4 cells (Fig. 3A). Annexin V
analysis showed that expression of miR-221 and/or miR-
222 significantly reduced cell apoptosis induced by
serum starvation (Fig. 3B). However, expression of
PUMA largely abrogated miR-221/222 effects on cell
apoptosis (Fig. 3C), suggesting that PUMA is a critical
target of miR-221 and miR-222 involved in cell
apoptosis.
As-miR-221/222 inhibits glioblastoma xenograft growth
accompanying PUMA upregulation
S i n c em i R - 2 2 1a n dm i R - 2 2 2a r ef r e q u e n t l ye l e v a t e di n
glioblastoma and play an important role in cell survival,
we further examined the effects of knockdown of miR-
221/222 on tumor growth. As shown in Fig. 4A, tumors
continued growing in both scramble and control groups.
However, As-miR-221/222 significantly reduced tumor
growth (p < 0.05). After 5 days of withdraw of the treat-
ment, tumor started to regrow. TUNEL assay analysis of
xenograft tumor taken at 28 days after treatment
revealed much more apoptosis in As-miR221/222 group
when compared to tumors from scramble and control
groups (Fig. 4B). We also histologically observed that
there were more neonatal micro-vessels, bigger tumor
cell nuclei, chromosomes stained a deeper blue, more
mitotic tumor cells and fewer necrotic foci in control
and scramble groups than those in As-miR221/222
group. Ki-67 staining shows that As-miR-221/222 trea-
ted tumors had a lower proliferation index compared
with the control groups (Fig. 4C). In addition, LNA-ISH
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erably reduced in As-miR221/222 group (Fig. 4D).
Immunohistochemical stanining analysis revealed that
PUMA levels were up-regulated in As-miR221/222
group (Fig. 4E), confirming the data in vitro that PUMA
as a direct target of miR-221/222. Additionally, Bax
expression was increased, whereas Bcl2 expression was
decreased in xenograft tumor sections (Fig. 4G, F).
These findings further indicate that miR-221/222 targets
PUMA and that As-miR-221/222 could be therapeutic
means for glioblastoma intervention.
Inverse correlation of expression of miR-221/222 and
PUMA in glioma tissues
Having demonstrated PUMA as a major target of miR-
221/222, we further investigated the correlation of
between miR-221/222 and PUMA expression in gliomas.
We examined 40 human glioma specimens with LNA-
ISH and immunohistochemical staining. Representative
images of miR-221/222 and PUMA were shown in
Fig. 5A. Upregulation of miR-221/222 was detected in 26
gliomas (Fig. 5B). Of the 26 tumors with elevated miR-
221/222, 21 (81%) had low levels of PUMA (P < 0.001).
Figure 1 As-miR-221/222 increases glioma apoptosis. (A) Identification of differential expression of miR-221/222 in glioma cell lines (1, A172;
2, TJ905; 3, TJ899; 4, U251; 5, TJ866; 6, H4; 7, LN229) by Northern blot analysis. (B) U251 and LN229 cells were transfected with As-miR-221/222,
and miR-221/222 expression level was detected by Northern blot assay. U6 was regarded as endogenous normalizer. (C) Annexin V analysis
showed that U251 and LN229 cells transfected with As-miR-221/222 displayed significantly more apoptosis than the other four groups. (D) U251
and LN229 cells were transfected with As-miR-221/222, and Bax and Bcl2 protein level was detected by Western blot assay. b-actin protein was
regarded as endogenous normalizer. (E) A significant increase in caspase 3/7 activity was detected in U251 and LN229 cells transfected with As-
miR-221/222. (F) U251 cells transfected with As-miR-221/222 showed a significantly greater collapse in mitochondrial membrane potential
compared with the other four groups. * P < 0.05 compared with control group, ** P < 0.01 compared with control group.
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Page 3 of 9Figure 2 PUMA was a direct target gene of miR-221/222. (A) Schematic representation of the putative binding sites in PUMA mRNAs 3’UTR
for miR-221/222 (identical seed sequences AGCUACAU as shown). Sequence alignment of miR-221, miR-222 and the conserved binding sites
among the different vertebrate species (Red, G:C pair or A:U pair; Blue, G:U pair). (B) U251 cells were transfected with As-miR-221/222, and PUMA
protein level was detected by Western blot assay. b-actin protein was regarded as endogenous normalizer. (C) H4 cells were transfected with
pMSCV-miR-221/222, and miR-221/222 and PUMA expression levels were detected by Northern blot and Western blot assay. U6 and b-actin
protein were regarded as endogenous normalizer. (D) pGL3-WT-PUMA-3’UTR-Luc and pGL3-MUT-PUMA-3’UTR-Luc reporters were transfected into
U251 cells transfected with As-miR-221 and/or As-miR-222. Luciferase activity was determined 48 h after transfection. The ratio of normalized
sensor to control luciferase activity is shown. Error bars represent standard deviation and were obtained from three independent experiments. (E)
U251 and LN229 cells were transfected with As-miR-221/222, and p53 protein level was detected by Western blot assay. b-actin protein was
regarded as endogenous normalizer. * P < 0.05 compared with control group, ** P < 0.01 compared with control group.
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222 presented high levels of PUMA. In addition, we
f o u n dt h a tm i R - 2 2 1 / 2 2 2e x p r e s s i o ni n c r e a s e ds i g n i f i -
cantly in high grade gliomas compared with low grade
gliomas.
Discussion
Previous studies have shown frequent upregulation of
miR-221/222 in human malignancies incuding glioblas-
toma [15]. MiR-221/222 regulate cell cycle through tar-
geting p27 and p57 [16-19]. In the present study, we
demonstrated the role of miR-221/222 in regulation of
cell apoptosis. Knockdown of miR-221/222 induced
change of mitochondrial membrane potential and cas-
pase-mediated apoptosis. Further, we proved that pro-
apoptotic protein PUMA was negatively regulated by
miR-221/222. In addition, local injection of As-miR-221/
222 reduced tumor growth and induced apoptosis in
xenograft model. These findings provide the evidence of
direct regulation of mitochondrial apoptotic pathway by
miR-221/222.
A mitochondrial-dependent step in apoptosis, invol-
ving mitochondrial outer membrane permeabilization
(MOMP), is associated with most pro-apoptotic stimuli.
This process is controlled by both pro- and anti-
apoptotic members of the Bcl2 family and leads to the
release of mitochondrial apoptotic factors such as cyto-
chrome c, Smac/DIABLO and Omi/HtrA2 into the cyto-
sol. Pro-apoptotic protein Bax induces a selective
process of MOMP through the formation of channels or
pores after oligomerization, allowing the release of pro-
teins localized within the intermembrane space such as
cytochrome c, which triggers caspase 9/3 activation to
induce the apoptotic phenotype [21]. However, Willis
had detected no association of PUMA with Bax [22].
Other studies identified that PUMA indirectly activated
Bax by binding and inactivating anti-apoptotic Bcl2
family members that include Bcl2 protein [23,24]. In our
study, we found that knockdown miR-221/222 could
downregulate Bcl2 and upregulate Bax by western blot
assay. In addition, the change of BAX and Bcl2 expres-
sion in xenograft study with U251 cells confirmed the
data in vitro. These results indicate that miR-221/222
negatively regulate PUMA which leads to decrease Bcl2
and increase BAX.
Our results proved that modulating effect of miR-221/
222 on PUMA by directly targeting PUMA. Bioinfor-
matics analysis showed that 3′UTR of PUMA mRNA
existed the highly conserved putative miR-221/222 bind-
ing sites. Luciferase reporter assay validated that PUMA
Figure 3 Expression of PUMA abrogates miR-221/222 survival function. (A) H4 cells were transfected pcDNA-PUMA (not including the
3’UTR), and PUMA expression was measured by Western blot assay. b-actin protein was regarded as endogenous normalizer. (B) H4 cells were
transfected with pMSCV-miR-221/222, then treated with serum starvation and cell apoptosis was Annexin V analysis. (C) H4 cells were transfected
with pcDNA-PUMA (not including the 3’UTR) and pMSCV-miR-221/222, and cell apoptosis, caspase activity and mitochondrial membrane
potential were measured by Annexin V analysis, caspase 3/7 activity assay and JC-1 staining. * P < 0.05 compared with control group, ** P <
0.01 compared with control group.
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established, As-miR-221/222 were injected in a multi-site injection manner every 3 days for 15 days. Tumor volumes were measured every 2
days during treatment. (B) TUNEL assay in xenograft tumor sections revealed that As-miR-221/222 induced cell apoptosis. (C) Ki-67 expression
was detected by immunohistochemistry assay in xenograft tumor sections. (D) Fluorescence in situ hybridization showed that As-miR-221/222
effectively inhibited the expression of miR-221 and miR-222. (E-G) PUMA, Bax and Bcl2 expression was detected by immunohistochemistry assay
in xenograft tumor sections. * P < 0.05 compared with control group.
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with U251 cells also shows that As-miR-221/222 treat-
ment reduces tumor growth accompanying increase of
PUMA expression and apoptosis. Further, there was an
inverse relationship between PUMA and miR-221/222
expression levels in glioma tissues. PUMA, as a key
mediator of p53-associated apoptosis, actually accounts
for nearly all of the apoptotic activity attributed to p53.
However, the expression level of p53 remained
unchanged after reduction of miR-221/222. Thus, these
finding suggest that PUMA is a core target of miR-221/
222 in cell apoptosis.
Conclusions
In summary, our data demonstrated that miR-221/222
induced cell survival by direct targeting PUMA, and
thus regulates mitochondrial pathway. We also provided
direct evidence using As-miR-221/222 as therapeutic
approaches for glioblastoma. The role of miR-221/222
in gilomagensis needs to be further investigated by
creating transgenic mouse model.
Methods
Cell culture and transfection
Human glioblastoma cells (A172, U251, H4, LN229),
retrovirus-packaging cells PT67 and the mouse fibro-
blast cell line NIH3T3 were obtained from the China
Academia Sinica Cell Repository, Shanghai, China.
Human glioblastoma cells (TJ905, TJ899, TJ866) were
established in our lab. The cells were maintained in Dul-
becco’sm o d i f i e dE a g l e ’s medium (DMEM) (Gibco) sup-
plemented with 10% fetal bovine serum (Gibco), 2 mM
glutamine (Sigma), 100 μg/ml penicillin (Sigma), and
100 μg/ml streptomycin (Sigma), and incubated at 37°C
with 5% CO2. Cell transfection were used Lipofectamine
2000 (Invitrogen) following manufacture instruction.
Plasmids, virus production and oligonucleotides
Human pMSCV-miR-221 and -miR-222 were kindly
provided by. R. Agami (The Netherlands Cancer Insti-
tute, Amsterdam, The Netherlands). The retroviruses
expressing miR-221 or miR-222 were obtained by trans-
fection of pMSCV-miR-221 and -miR-222 into PT67
packaging cells and selected with blasticidin S (10 μg/
ml) for six weeks. The viruses were tittered in NIH3T3
cells. Once cells grew to 60% confluence, cells were
infected with pMSCV-miR-221 and/or pMSCV-miR-222
at a multiplicity of infection (MOI) of 50. HA-tagged
wild-type PUMA in pCDNA3 was obtained from B. Vol-
gelstein [25]. pGL3-WT-PUMA-3′UTR-Luc reporter was
created by ligation of PCR products of 3′UTR of PUMA
into the XbaI site of the pGL3 control vector (Promega,
USA). The primers for PCR amplification are: PUMA-3′
UTR-Forward: 5′-TCA TGA ATTC GCC CCT CCC
ACC TCC TGA CAC CCT GGC CAG CGC GGG
GGA CTT TCT CTG C and PUMA-3′UTR-Reverse:
5′-CGC CCC CGG GAC AGG CAG GGC TGG GAG
TCC AGT ATG CTA CAT GGT GCA GAG AAA
GTC CC-3′. pGL3-MUT-PUMA-3′UTR-Luc reporter
was generated from pGL3-WT-PUMA-3′UTR-Luc
reporter by deleting the binding site for miR-221/222.
The 2′-OMe-oligonucleotides were chemically synthe-
sized and purified by high-performance liquid chroma-
tography by GenePharma Co., Ltd. (Shanghai, China).
Figure 5 MiR-221/222 inversely correlate with PUMA expression in glioma tissues. (A) Expression of miR-221/222 and PUMA was analyzed
in representative of gliomas with LNA-ISH and immunohistochemical staining. Expression levels of miR-221/222 and PUMA were quantified as
described in methods. (B) Chisquare test analysis of miR-221/222 and PUMA expression. The inverse correlation is significant (p < 0.001).
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5′-AGCUACAUUGUCUGCUGGGUUUC-3′;2 ′-OMe-
As-miR-222 (As-miR-222), 5′-AGCUACAUCUGGCUA-
CUGGGU-3′. 200 pmol As-miR-221 and/or As-miR-222
were transfected using Lipofectamine 2000 (Invitrogen).
Cells transfected with scrambled 2′-OMe oligonucleo-
tides (scramble) were used as control.
RNA extraction and Northern blot analysis
Total RNA was isolated from cells using TRIzol reagent
(Invitrogen) as previously described [26]. For Northern
blotting, total RNAs (20 μg) were separated on 12%
denaturing polyacrylamide gels, and then transferred to
Hybond N+ nylon membrane (Ambion). Following the
UV cross-linked, he membrane was hybridized with
digoxigenin (DIG)-labeled miR-221 and miR-222 probes
overnight in a buffer containing 5× SSC, 20 mmol/L
Na2HPO4 (pH 7.2), 7% SDS, 1× Denhardt’s solution and
0.2 mg/mL salmon sperm DNA. The membrane was
washed with 1× SSC/1% SDS at 50°C. After equilibration
in detection buffer, blots were detected with a DIG
Luminescent Detection Kit (Roche, USA) and analyzed
by GeneGenius.
Western blot, miRNA locked nucleic acid (LNA) in situ
hybridization, immunohistochemistry and luciferase
reporter assay
Western blot, miRNA-LNA in situ hybridization and
immunohistochemistry were performed as previously
described [27]. MiR-221 and miR-222-LNA oligonucleo-
tides contained locked nucleic acids at five locations
(underlined): 5′-GAA ACC CAG CAG ACA ATG TAG
CT-3′ (miR-221); 5′-GAG ACC CAG TAGC C AGAT
GTA GCT-3′ (miR-222). For reporter assay, cells were
cultured in 96-well plates and transfected with pGL3-
PUMA-3′UTR-Luc, and As-miR-221 and/or As-miR-221.
Following 48 h incubation, luciferase activity was mea-
sured using a dual-luciferase reporter system (Promega).
Apoptosis
48 h after transfection, apoptosis in cultured cells was
evaluated with annexin V labeling, caspase 3/7 activity
and mitochondrial membrane potential. For the annexin
V assay, an annexin V-FITC labeled Apoptosis Detec-
tion Kit (Abcam) was used according to the manufac-
turer’s protocol. Caspase 3/7 activity was measured
using Caspase-Glo 3/7 reagent (Promega). Mitochon-
drial membrane potential was determined with cationic
dye JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′- tetraethylbenzi-
midazolylcarbocyanine-chloride/C25H27Cl3N4) staining
[21]. Briefly cells were harvested and first stained with
PI. Following wash twice with PBS, cells were incubated
with 10 mg/ml JC-1 for 20 min at room temperature
and then analyzed with FACSCalibur to detect green
fluorescence at excitation/emission wavelengths of 485/
530 nm and red fluorescence at excitation/emission
wavelengths of 485/590 nm. TUNEL assay was used to
detect the apoptosis in tumor specimens and was per-
formed as previously described [15].
Nude Mouse Tumor Xenograft Model and As-miR-221/222
treatment
U251 glioma cells were subcutaneously injected to
5 - w e e ko l df e m a l en u d em i c e( C a n c e rI n s t i t u t eo fT h e
Chinese Academy of Medical Science). When the tumor
volume reached 50 mm
3, the mice were randomly
divided into three groups (ten mice per group) which
were treated with 200 pmol scramble oligo, As-miR-221
and As-miR-222 in 10 μl Lipofectamine or PBS through
local injection of xenograft tumor in multiple sites. The
treatment was performed once every 3 days for 15 days.
The tumor volume was measured with a caliper every
2 days, using the formula: volume = length × width
2 /2.
Patients and samples
From 40 glioma patients, we obtained 40 primary tumor
samples during surgical resection of the lesion. Immedi-
ately after surgery, samples were snap-frozen and stored
in liquid nitrogen. Histological diagnosis and grading of
tumors were carried out with WHO criteria (World
Health Organization, 2007). A total of 18 tumors were
classified as low-grade gliomas, 10 as anaplastic astrocy-
tomas, and the remaining 12 as glioblastoma multi-
formes (GBMs). Then miRNA-LNA in situ
hybridization and immunohistochemistry were per-
formed. Sections with no labeling or with fewer than
5% labeled cells were scored as 0. Sections were scored
as a 1 with labeling of 5-30% of cells, as a 2 with 31-
70% of cells and as a 3 with labeling of ≥71%. The
staining intensity was scored similarly, with 0 used for
negative staining, 1 for weakly positive, 2 for moderately
positive and 3 for strongly positive. The scores for the
percentage of positive tumor cells and for the staining
intensity were added to generate an immunoreactive
score for each specimen. The product of the quantity
and intensity scores were calculated such that a final
score of 0-1 indicated negative expression (-), 2-3 indi-
cated weak expression (+), 4-5 indicated moderate
expression (++) and 6 indicated strong expression (+++).
Each sample was examined separately and scored by
two pathologists.
Statistical Analysis
Statistical evaluation for data analysis was determined by
t test. Differences with P < 0.05 were considered statisti-
cally significant
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